Deregulation of SYCP2 predicts early stage human papillomavirus-positive oropharyngeal carcinoma: A prospective whole transcriptome analysis

Cancer Science

Volumn 106, Issue 11, 2015, Pages 1568-1575

  Masterson, Liam ^a,b   Sorgeloos, Frederic ^a   Winder, David ^a   Lechner, Matt ^c   Marker, Alison ^b   Malhotra, Shalini ^b   Sudhoff, Holger ^d   Jani, Piyush ^b   Goon, Peter ^a   Sterling, Jane ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d Bielefeld Academic Teaching Hospital   (Germany)

Author keywords

Diagnosis by tumor markers and biomarkers; Human papillomavirus; mRNA expression analysis; Oropharyngeal carcinoma; Rb p16 related genes

Indexed keywords

CRCT1 PROTEIN; DLG2 PROTEIN; PROTEIN; PROTEIN P53; SECRETED FRIZZLED RELATED PROTEIN 1; SYCP2 PROTEIN; TRANSCRIPTOME; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; SYCP2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER TISSUE; CARCINOMA IN SITU; CLINICAL ARTICLE; EPITHELIUM; FEMALE; GENE EXPRESSION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; LASER CAPTURE MICRODISSECTION; MALE; NONHUMAN; OROPHARYNGEAL SQUAMOUS CELL CARCINOMA; OROPHARYNX CARCINOMA; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SQUAMOUS CELL CARCINOMA; TUMOR INVASION; WART VIRUS; AREA UNDER THE CURVE; BIOSYNTHESIS; COMPLICATION; GENE EXPRESSION PROFILING; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KAPLAN MEIER METHOD; METABOLISM; MOLECULAR GENETICS; MORTALITY; OROPHARYNX TUMOR; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; VIROLOGY;

ADULT; AREA UNDER CURVE; BIOMARKERS, TUMOR; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KAPLAN-MEIER ESTIMATE; LASER CAPTURE MICRODISSECTION; MALE; MOLECULAR SEQUENCE DATA; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; ROC CURVE; TRANSCRIPTOME;

EID: 84954408132     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12809     Document Type: Article

References (47)

1. Mehanna H, Beech T, Nicholson T et al. The prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer: a systematic review and meta-analysis of trends by time and region. Head Neck 2012; 35: 747-55.
2. Chaturvedi AK, Engels EA, Pfeiffer RM et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011; 29: 4294-301.
3. Chaturvedi AK, Anderson WF, Lortet-Tieulent J et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol 2013; 31: 4550-9.
4. Hoffmann M, Ihloff AS, Gorogh T, Weise JB, Fazel A, Krams M. p16(INK4a) overexpression predicts translational active human papillomavirus infection in tonsillar cancer. Int J Cancer 2010; 127: 1595-602.
5. Oliver M, Eeles R, Holstein M, Khan MA, Harris CC, Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002; 19: 607-14.
6. Gillison ML, Zhang Q, Jordan R et al. Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol 2012; 10: 2102-11.
7. Licitra L, Perrone F, Bossi P et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 2006; 24: 5630-6.
8. Masterson L, Moualed D, Liu ZW et al. De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma: a systematic review and meta-analysis of current clinical trials. Eur J Cancer 2014; 50: 2636-48.
9. Masterson L, Moualed D, Masood A et al. De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma. Cochrane Database Syst Rev 2014; 2: CD010271.
10. van Zeeburg HJ, Graveland AP, Brink A et al. Generation of precursor cell lines from preneoplastic fields surrounding head and neck cancers. Head Neck 2013; 35: 568-74.
11. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer 2011; 11: 9-22.
12. Miller CS, Johnstone BM. Human papillomavirus as a risk factor for oral squamous cell carcinoma: a meta-analysis, 1982-1997. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 91: 622-35.
13. Jayaprakash V, Reid M, Hatton E et al. Human papillomavirus types 16 and 18 in epithelial dysplasia of oral cavity and oropharynx: a meta-analysis, 1985-2010. Oral Oncol 2011; 47: 1048-54.
14. Näsman A, Nordfors C, Holzhauser S et al. Incidence of human papillomavirus positive tonsillar and base of tongue carcinoma: a stabilisation of an epidemic of viral induced carcinoma? Eur J Cancer 2015; 51(1): 55-61.
15. Chaudhary AK, Singh M, Sundaram S, Mehrotra R. Role of human papillomavirus and its detection in potentially malignant and malignant head and neck lesions: updated review. Head Neck Oncol 2009; 25(1): 22.
16. Ang K, Harris J, Wheeler R et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35.
17. Psyrri A, Sasaki C, Vassilakopoulou M, Dimitriadis G, Rampias T. Future directions in research, treatment and prevention of HPV-related squamous cell carcinoma of the head and neck. Head Neck Pathol 2012; 6(Suppl 1): S121-8.
18. Sobin LH, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumors, 7th edn. Oxford: Wiley-Blackwell, 2009.
19. Winder DM, Ball SL, Vaughan K et al. Sensitive HPV detection in oropharyngeal cancers. BMC Cancer 2009; 9: 440.
20. Gravitt PE, Peyton CL, Alessi TQ et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000; 38: 357-61.
21. de Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ. The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol 1995; 76: 1057-62.
22. Sotlar K, Stubner A, Diemer D et al. Detection of high-risk human papillomavirus E6 and E7 oncogene transcripts in cervical scrapes by nested RT-polymerase chain reaction. J Med Virol 2004; 74: 107-16.
23. Masterson L, Winder D, Marker A et al. Investigating the role of human papillomavirus in squamous cell carcinoma of the temporal bone. Head Neck Oncol 2013; 5(2): 22.
24. ® HPVzr Probes In Situ Hybridization (ISH) Staining of Cervical Tissue. Tucson, AZ, USA: Ventana Medical Systems, Incorporated, 2006.
25. Laborde RR, Wang VW, Smith TM et al. Transcriptional profiling by sequencing of oropharyngeal cancer. Mayo Clin Proc 2012; 87: 226-32.
26. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001; 98: 5116-21.
27. Li CI, Su PF, Guo Y, Shyr Y. Sample size calculation for differential expression analysis of RNA-seq data under Poisson distribution. Int J Comput Biol Drug Des 2013; 6: 358-75.
28. Sabo E, Meitner PA, Tavares R et al. Expression analysis of Barrett's esophagus-associated high-grade dysplasia in laser capture microdissected archival tissue. Clin Cancer Res 2008; 14: 6440-8.
29. Slebos RJ, Yi Y, Ely K et al. Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res 2006; 12(3): 701-9.
30. Syrjanen S. HPV infections and tonsillar carcinoma. J Clin Pathol 2004; 57: 449-55.
31. Pannone G, Santoro A, Papagerakis S, Lo Muzio L, De Rosa G, Bufo P. The role of human papillomavirus in the pathogenesis of head & neck squamous cell carcinoma: an overview. Infect Agent Cancer 2011; 6: 4.
32. Pyeon D, Newton MA, Lambert PF et al. Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers. Cancer Res 2007; 67: 4605-19.
33. Walter V, Yin X, Wilkerson MD et al. Molecular subtypes in head and neck cancer exhibit distinct patterns of chromosomal gain and loss of canonical cancer genes. PLoS ONE 2013; 8(2): e56823.
34. Mooren J, Gültekin S, Straetmans J et al. P16INK4A immunostaining is a strong indicator for high-risk-HPV-associated oropharyngeal carcinomas and dysplasias, but is unreliable to predict low-risk-HPV-infection in head and neck papillomas and laryngeal dysplasias. Int J Cancer 2014; 134: 2108-17.
35. Beachler DC, Viscidi R, Sugar EA et al. A longitudinal study of human papillomavirus 16 L1, e6, and e7 seropositivity and oral human papillomavirus 16 infection. Sex Transm Dis 2015; 42: 93-7.
36. Kreimer AR, Bhatia RK, Messeguer AL, González P, Herrero R, Giuliano AR. Oral human papillomavirus in healthy individuals: a systematic review of the literature. Sex Transm Dis 2010; 37: 386-91.
37. Kreimer AR, Pierce Campbell CM, Lin HYFW et al. Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study. Lancet 2013; 382: 877-87.
38. Gillison ML, Broutian T, Pickard RK et al. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA 2012; 307: 693-703.
39. Martinez I, Wang J, Hobson KF, Ferris RL, Khan SA. Identification of differentially expressed genes in HPV-positive and HPV-negative oropharyngeal squamous cell carcinomas. Eur J Cancer 2007; 43: 415-32.
40. Lambert P, Newton M, Ahiquist P. HPV-Positive Biomarkers for Cervical and Head and Neck Cancers. 2015 [Cited 01 April 2015.] Available from URL: http://www.warf.org/technologies/summary/P07312US.cmsx.
41. Schache AG, Liloglou T, Risk JM et al. Evaluation of human papilloma virus diagnostic testing in oropharyngeal squamous cell carcinoma: sensitivity, specificity, and prognostic discrimination. Clin Cancer Res 2011; 17: 6262-71.
42. Robinson M, Schache A, Sloan P, Thavaraj S. HPV specific testing: a requirement for oropharyngeal squamous cell carcinoma patients. Head Neck Pathol 2012; 6(Suppl 1): S83-90.
43. Posner MR, Lorch JH, Goloubeva O et al. Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol 2011; 22: 1071-7.
44. Rischin D, Young RJ. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 2010; 28: 4142-8.
45. O'Sullivan B, Huang SH, Siu LL et al. Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol, 2013; 31: 543-50.
46. Kanehisa M, Goto S, Sato Y, Kawashima M, Furumichi M, Tanabe M. Data, information, knowledge and principle: back to metabolism in KEGG. Nucleic Acids Res 2014; 42: D199-205.
47. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-55.